Patient information may be excluded from EU pharmaceutical package
This article was originally published in SRA
Executive Summary
The European Commission says that it is likely to delay a legislative proposal on the provision of information to patients, which is part of its larger “pharmaceutical package” that was unveiled late last year1,2. Faraz Kermani reports from the European Federation of Pharmaceutical Industries and Associations annual general meetings in Seville, Spain, on 13-15 May.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.